Bioprocessing technologies company Repligen is acquiring Avitide, and its biologics purifying technology, in a $150 million cash and stock deal. Repligen said Avitide will help it meet growing demand for gene therapy solutions.
In an article published in the journal mAbs Monday, executives from Adimab alleged that MIT's Ram Sasisekharan copied prior monoclonal antibody research. Visterra, a company Sasisekharan founded that had been developing one of the antibodies, was acquired by Otsuka for $430M last year.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases